COLUMBIA, Md., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, will present advanced clinical and scientific research at the Desert Foot Conference.
List of events supported by Osiris include:
On Wednesday, October 19:
Dr. Lawrence Lavery, DPM, MPH will be speaking on “The use of Viable Placental Membranes in Complex Wounds” at the Breakfast Symposium from 7:15 a.m. to 8:00 a.m.
On Thursday, October 20:
A Grafix® Workshop, which will provide “hands on” experience and discussion of Grafix scientific and clinical evidence, will take place from 10:05 a.m. to 1:05 p.m.
A CME lecture “Clinical and Scientific Advances in the Use of Cryopreserved Placental Membranes in Complex Wounds” will be presented by Dr. Gary Gibbons, MD, from 3:30 p.m. to 3:55 p.m.
On Friday, October 21:
A Stravix™ workshop, which will provide “hands on” experience and discussion of Stravix scientific and clinical evidence, will take place from 10:30 a.m. to 1:30 p.m.
A lecture “The Use of Viable Cryopreserved Placental Tissue for Surgical Applications” will be presented by Dr. Kyle Sundblad, DPM, from 3:10 p.m. to 3:35 p.m.
On Saturday, October 22:
Dr. Jonathan Brantley, DPM, will be presenting a CME lecture “Placental Membranes: A Molecular Review” from 8:20 a.m. to 8:45 a.m.
Dr. Alberto Abrebaya, DPM will be speaking on “The use of Viable Placental Membranes in Complex Wounds” as part of the Indian Health Service Limb Preservation Summit from 9:40 a.m. to 10:10 a.m.
“Case Study: Evaluation of the Use of Viable Cryopreserved Human Placental Membrane for the Treatment of a Complex Diabetic Foot Ulcer with Exposed Bone and Tendon” (by M Griages, S Kommareddy, L Carranza and K Galli)
“Viable Cryopreserved Placental Allografts for the Treatment of Post-Surgical Amputation Wounds in High Risk Patients” (by K McGinness)
“The Use of a Viable Cryopreserved Umbilical Tissue Allograft for Bunionectomy: Three Cases” (by J Brantley and J Richason)
“The Surgical Use of a Viable Cryopreserved Umbilical Tissue in Partial Foot Amputations: a Three Patient Case Series” (by J Brantley and J Richason)
“The Surgical Use of a Viable Cryopreserved Umbilical Tissue in First Metatarsophalangeal Joint Arthrodesis: a Three Patient Case Series” (by J Brantley and J Richason)
Osiris Therapeutics will also be exhibiting at the Desert Foot meeting at booth 17.
About Osiris Therapeutics
Osiris Therapeutics, Inc., based in Columbia, Maryland, is a world leader in researching, developing and marketing regenerative medicine products that improve health and lives of patients and lower overall healthcare costs. Having developed the world's first approved stem cell drug, the company continues to advance its research and development in biotechnology by focusing on innovation in regenerative medicine - including bioengineering, stem cell research and viable tissue based products. Osiris has achieved commercial success with products in orthopaedics, sports medicine and wound care, including BIO4®, Cartiform®, Grafix® , TruSkinTM and StravixTM. Osiris, Grafix, Cartiform, TruSkin and Stravix are trademarks of Osiris Therapeutics, Inc. BIO4® is a trademark of Howmedica Osteonics Corp. More information can be found on the company's website, www.Osiris.com (OSIR-G).
For additional information, please contact: Diane Savoie Osiris Therapeutics, Inc. (443) 545-1834 OsirisPR@Osiris.com
Source:Osiris Therapeutics, Inc.